Investing.com - Enveric Biosciences (NASDAQ: ENVB) reported third quarter EPS of $-1.300, $0.04 worse than the analyst estimate of $-1.260. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Enveric Biosciences's stock price closed at $1.520. It is down -30.910% in the last 3 months and down -55.290% in the last 12 months.
Enveric Biosciences saw positive EPS revisions and negative EPS revisions in the last 90 days. See Enveric Biosciences's stock price’s past reactions to earnings here.
According to InvestingPro, Enveric Biosciences's Financial Health score is "weak performance".
Check out Enveric Biosciences's recent earnings performance, and Enveric Biosciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar